Award
National Institute of Allergy and Infectious Diseases 5R01AI189899-02
Unraveling the spectrum of intrabacterial amide hydrolysis to develop new classes of pyrazinoic acid prodrugs against pyrazinamide resistant Mycobacterium tuberculosis
Recipient
Rutgers Biomedical and Health Sciences, Newark, NJ, United States
Award Amount
$792,528.00
Ceiling
$792,528.00
Awarded
May 07, 2026
Identifier
5R01AI189899-02
A NIH-funded research project awarded to Rutgers Biomedical and Health Sciences to develop new classes of pyrazinoic acid prodrugs targeting pyrazinamide resistant Mycobacterium tuberculosis by studying intrabacterial amidase activity and optimizing drug candidates.
Description
This research grant focuses on developing new anti-tuberculosis drugs by leveraging the activity of Mycobacterium tuberculosis amidases to activate prodrugs, aiming to overcome existing drug resistance issues. The project aims to characterize diverse Mtb amidases and design new pyrazinoic acid-amide prodrugs effective against both PZA susceptible and resistant Mtb strains, followed by pharmacokinetic studies in a mouse model.